Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : corgenix -- Ignore unavailable to you. Want to Upgrade?

To: LANCE B who wrote (48)	11/10/1998 8:52:00 AM
From: charles moore	Respond to of 191

There is News out. Something about COGX filing a 510 Form for a Monoclonal test with the FDA. The only place I could find this info was at msnbc.com The site is free. All you have to do is download their plug-in and it seems to feature news faster and also plug in your zip code and it will give you your weather for 4 days . Charles

To: LANCE B who wrote (48)	11/10/1998 8:53:00 AM
From: Benoit Desrochers	Respond to of 191

Corgenix Submits Filing to FDA for Clearance of New Test for Measuring Protein S Deficiency DENVER, Nov. 10 /PRNewswire/ -- Corgenix Medical Corporation (OTC Bulletin Board: COGX - news) announced the filing of a 510k application with the U.S. Food & Drug Administration (FDA) for clearance to market its new Monoclonal Free Protein S test kit. Protein S is a protein which plays an important physiological role in the anticoagulant (inhibiting clot formation) system. A Protein S deficiency, either congenital or acquired, may lead to serious thrombotic (blood clots) events such as thrombophlebitis, deep vein thrombosis, or pulmonary embolism (blood clots in the lungs). A congenital deficiency of Protein S may have a prevalence as high as 15 to 18 percent in young patients (less than 35 years of age) with a history of thrombosis. Acquired Protein S deficiency may be seen during pregnancy, oral contraceptive or oral anticoagulant therapy, liver disease, diabetes mellitus, postoperative complications, septicemia and various inflammatory syndromes. Because the new Corgenix test utilizes a monoclonal antibody specific for Free Protein S, it provides a more specific method for laboratory diagnosis of Protein S deficiency. This technology also offers advantages over other methods as it is performed more rapidly, is less labor intensive and provides improved accuracy for the laboratory diagnosis of Protein S deficiency. Luis R. Lopez, M.D., chairman and CEO of Corgenix, said, ''The potential of this new test is significant and complements our other clotting disorder products. Together with Corgenix's other vascular disease tests, the Monoclonal Free Protein S Antigen kit provides the physician with a more complete picture for an accurate diagnosis of Protein S deficiency.'' Corgenix Medical Corporation is based in metropolitan Denver and is focused on the development and promotion of specialized diagnostic test kits for vascular diseases, immunological disorders, as well as bone diseases such as osteoporosis and joint diseases such as arthritis. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. Statements in this release that are not strictly historical are ''forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995, and should be considered as subject to various risks and uncertainties that could cause actual results to differ materially from those anticipated. For more information, contact Chris Wolfe, investor relations coordinator of Corgenix at (303) 457-4345, or Kyle Freeman of Corporate Relations Group at 1-800-444-4980. Corporate Relations Group is a subsidiary of Stratcomm Media, Ltd. (OTC Bulletin Board: SMMM - news). biz.yahoo.com